Morgan Stanley Sticks to Their Buy Rating for Akeso, Inc. (9926)
Morgan Stanley analyst Jack Lin has reaffirmed a Buy rating for Akeso, Inc. (9926) as of November 9, with a price target of HK$215.00. The overall analyst consensus for Akeso is a Strong Buy, with an average price target of HK$187.65. Lin specializes in the Healthcare sector and has a track record of -5.9% average return and a 35.71% success rate on his stock recommendations.
Morgan Stanley analyst Jack Lin maintained a Buy rating on Akeso, Inc. on November 9 and set a price target of HK$215.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Lin covers the Healthcare sector, focusing on stocks such as Zai Lab Ltd, Akeso, Inc., and RemeGen Co. Ltd. Class H. According to TipRanks, Lin has an average return of -5.9% and a 35.71% success rate on recommended stocks.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Akeso, Inc. with a HK$187.65 average price target.
